Scholar Rock Holding buy Raymond James
Start price
28.03.24
/
50%
€14.70
Target price
28.03.25
€27.73
Performance (%)
-7.48%
Price
26.04.24
€13.60
Summary
This prediction is currently active. With a performance of -7.48%, the BUY prediction by Raymond_James is trending in the wrong direction. This prediction currently runs until 28.03.25. The prediction end date can be changed by Raymond_James at any time. Raymond_James has 50% into this predictionScholar Rock is a clinical-stage biopharmaceutical company that engages in the discovery and development of innovative medicines to treat serious diseases in patients that currently have limited or no treatment options. Their pipeline consists of a number of product candidates that target growth factor signaling pathways within the human body. These products hold potential for the treatment of multiple diseases, including neuromuscular disorders, cancer, and fibrosis. Scholar Rock, which trades under the symbol SRRK, is listed on the NASDAQ stock exchange.
Performance without dividends (%)
| Name | 1w |
|---|---|
| Scholar Rock Holding | 3.817% |
| iShares Core DAX® | 2.594% |
| iShares Nasdaq 100 | 3.553% |
| iShares Nikkei 225® | 0.687% |
| iShares S&P 500 | 2.209% |
Comments by Raymond_James for this prediction
In the thread Scholar Rock Holding diskutieren
Scholar Rock Holding Co. (NASDAQ: SRRK) is now covered by analysts at Raymond James. They set a "strong-buy" rating and a $30.00 price target on the stock.
Ratings data for SRRK provided by MarketBeat